Prescient will further the development and commercialization of the Infiniti Neural Response Panel to identify patients who may be at risk for opioid use disorder.
The Competition and Markets Authority is in charge of promoting competition and reducing anti-competitive activities in the UK.
To help fund the acquisition, Yourgene Health is planning to sell at least £10.0 million in newly issued shares to institutional investors.
The firm originally raised $55.5 million in the round in February 2018, and said investors added $30 million in December and another $20 million more recently.
The company presented new data on the performance of a multi-pronged liquid biopsy assay in detecting colorectal cancers across a range of clinical stages.
The acquisition will result in a new DLS division called HudsonAlpha Discovery that will provide a range of services to the pharma, biotech, and diagnostics industries.
Under the agreement, Bellwether researchers will join the team advancing Guardant's LUNAR early cancer detection and monitoring assays.
The company said that it plans to use Protagen's assets to further the development and commercialization of its EarlyCDT cancer diagnostics.
DermTech develops diagnostics for skin cancer and other skin diseases, and provides molecular pathology services through its CLIA-certified lab.
The firm said the purchase will allow it to better provide software tools to customers in the chemistry, pharmaceutical, and analytical laboratory markets.
A Harvard University professor has been charged with making false claims regarding funds he received from China, the New York Times reports.
Discover magazine reports that animal dissections might dissuade students from science careers, but that a firm has developed synthetic frogs for dissections.
Nature News reports that a US panel is reviewing current guidelines for federally funded gain-of-function viral research.
In PNAS this week: de novo mutation patterns among the Amish, an alternative RNA-seq method, and more.